



Summary of NICE Guidelines

Title	Bivalirudin for the treatment of ST-segment-elevation myocardial infarction.
NICE Reference	NICE technology appraisal guidance 230 (TA230)
Date of Review:	July-2014
Date of Publication	July-2011
Summary of Guidance	<ul style="list-style-type: none">• Bivalirudin is a direct thrombin inhibitor.• Bivalirudin is already in use in the UK and both patients and clinicians are in favour of its continued use. Bivalirudin is easier to use than abciximab (glycoprotein IIb/IIIa inhibitor) because the solution is easier to prepare and administer.• The clinical effectiveness of bivalirudin in combination with aspirin and clopidogrel is based on evidence from the HORIZONS-AMI trial that compared a strategy of bivalirudin with one using heparin plus glycoprotein IIb/IIIa inhibitors (both treatment arms receiving aspirin and clopidogrel). The primary outcome of major bleeding and secondary outcomes of all-cause mortality and cardiac mortality showed statistically significant advantages for treatment with bivalirudin over treatment with heparin plus glycoprotein IIb/IIIa inhibitor.• Cost effectiveness: The NICE Evidence Review Group (ERG) conducted exploratory analyses to check that the manufacturer's submitted economic analysis was robust. The ERG was satisfied that the manufacturer's model, which suggests that a bivalirudin-based intervention dominates heparin plus glycoprotein IIb/IIIa inhibitor, was robust to sensitivity analyses.• Key Conclusion: Bivalirudin in combination with aspirin and clopidogrel is recommended for the treatment of adults with ST-segment-elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (sometimes called balloon angioplasty or stenting).
Impact on Lab (See below)	■ None
Lab professionals to be made aware	Not applicable.
Please detail the impact of this guideline.	No impact.

Impact on Lab

- None:** This NICE guideline has no impact on the provision of laboratory services
- Moderate:** This NICE guideline has information that is of relevance to our pathology service and may require review of our current service provision.
- Important:** This NICE guideline is of direct relevance to our pathology service and will have a direct impact on one or more of the services that we currently offer.

Produced by: Phillip Monaghan

Reviewed by: Dr Joanne Adaway